Fapon showcases AI-engineered enzymes and Alzheimer’s diagnostic solutions at ADLM 2026

Fapon will present novel AI-engineered enzymes for molecular diagnostics and a comprehensive portfolio of raw materials and blood-based bulk reagents for Alzheimer’s disease at booth 3161 at ADLM 2026. By combining advanced assay components with localized support, Fapon aims to strengthen end-to-end IVD solutions for North American manufacturers and clinical laboratories.

New AI-engineered enzymes and Alzheimer’s disease reagents

Fapon will debut its AI-engineered enzymes ProPrime II and MeloScript III for molecular diagnostics. These enzymes are designed to deliver significant improvements in sensitivity, speed, and robustness for PCR and qPCR workflows, supporting more reliable nucleic acid testing in clinical and research settings.

Both enzymes are backed by full freedom-to-operate with proprietary intellectual property, and Fapon offers custom development services for partners seeking tailored enzyme formulations.

Responding to the growing global demand for early Alzheimer’s disease diagnosis, Fapon will also highlight a full suite of raw materials and blood-based bulk reagents covering mainstream Alzheimer’s disease biomarkers. Manufactured under ISO 13485, this portfolio is designed to help IVD manufacturers accelerate the development of blood-based Alzheimer’s assays from concept to clinic, supporting the shift toward minimally invasive diagnostic solutions.

Complete IVD portfolio from raw materials to instruments

In addition to its new product launches, Fapon will showcase its Shine i-Series CLIA analyzers, including the Shine i1000 and Shine i3000, which will be available for live demonstration at ADLM 2026. This open-system instrument series covers a range of throughputs and supports more than 70 in-house reagent assays, enabling laboratories to expand their chemiluminescence immunoassay testing menus.

Complementing the instrument display, Fapon will feature key raw materials and bulk reagents for immunoassay development. These include antibodies for small-molecule sandwich assays, notably vitamin D (25-OH VD), estradiol (E2), and thyroxine (FT4/T4).

Fapon will also present mouse-free IgG blockers as a preferred choice for animal-origin-free raw materials, as well as recombinant controls designed to enhance lot-to-lot consistency. Together, these components reflect Fapon’s focus on providing validated, performance-driven solutions that simplify assay development and support improved diagnostic accuracy.

Strengthening North America-focused IVD support

Guided by its ‘In America, For America’ approach, Fapon’s presence at ADLM 2026 underscores its accelerating investment in the North American IVD market. The company has established a US-based infrastructure to serve North American customers with greater speed and reliability, including research and development and production facilities located on US soil. This local footprint is intended to provide faster technical support and enhanced supply chain resilience for regional partners.

Fapon’s localized operations are supported by a comprehensive quality management system, with ISO 13485, ISO 9001, ISO 14001, and ISO 45001 certifications. These certifications help ensure that every product meets the consistency, safety, and compliance standards required by US laboratories and IVD manufacturers, reinforcing Fapon’s long-term commitment to the North American diagnostics ecosystem.

Follow SelectScience throughout ADLM 2026 for exclusive interviews, daily round-up articles, Scientists' Choice Awards^® coverage, and the latest news from the exhibition floor.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>